IL283754A - Anti-claudin antibodies, preparations containing them and their uses - Google Patents

Anti-claudin antibodies, preparations containing them and their uses

Info

Publication number
IL283754A
IL283754A IL283754A IL28375421A IL283754A IL 283754 A IL283754 A IL 283754A IL 283754 A IL283754 A IL 283754A IL 28375421 A IL28375421 A IL 28375421A IL 283754 A IL283754 A IL 283754A
Authority
IL
Israel
Prior art keywords
compositions
same
claudin antibodies
claudin
antibodies
Prior art date
Application number
IL283754A
Other languages
English (en)
Hebrew (he)
Original Assignee
Zlip Holding Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zlip Holding Ltd filed Critical Zlip Holding Ltd
Publication of IL283754A publication Critical patent/IL283754A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL283754A 2018-12-07 2021-06-06 Anti-claudin antibodies, preparations containing them and their uses IL283754A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CNPCT/CN2018/119797 2018-12-07
PCT/CN2019/123588 WO2020114480A1 (en) 2018-12-07 2019-12-06 Anti-claudin antibodies and uses thereof

Publications (1)

Publication Number Publication Date
IL283754A true IL283754A (en) 2021-07-29

Family

ID=70975310

Family Applications (1)

Application Number Title Priority Date Filing Date
IL283754A IL283754A (en) 2018-12-07 2021-06-06 Anti-claudin antibodies, preparations containing them and their uses

Country Status (12)

Country Link
US (1) US20210380680A1 (cg-RX-API-DMAC7.html)
EP (1) EP3891183A4 (cg-RX-API-DMAC7.html)
JP (1) JP7458399B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210100655A (cg-RX-API-DMAC7.html)
CN (1) CN113423735B (cg-RX-API-DMAC7.html)
AU (1) AU2019391204A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021011014A2 (cg-RX-API-DMAC7.html)
CA (1) CA3122135A1 (cg-RX-API-DMAC7.html)
IL (1) IL283754A (cg-RX-API-DMAC7.html)
MX (1) MX2021006681A (cg-RX-API-DMAC7.html)
SG (1) SG11202105885WA (cg-RX-API-DMAC7.html)
WO (1) WO2020114480A1 (cg-RX-API-DMAC7.html)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210109520A (ko) 2018-12-28 2021-09-06 쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 항체 및 이의 용도
JP7840511B2 (ja) 2019-02-01 2026-04-06 石▲薬▼集▲団▼巨石生物制▲薬▼有限公司 抗クローディン18抗体及びそれらの使用の方法
CA3178855A1 (en) * 2020-06-19 2021-12-23 Innovent Biologics (Suzhou) Co., Ltd. Anti-claudin18.2 antibody and use thereof
CN111808194B (zh) * 2020-07-13 2021-04-20 北京凯因科技股份有限公司 一种结合密蛋白的用于治疗癌症的人源化抗体
EP4222174A4 (en) * 2020-09-30 2025-02-12 Nanjing GenScript Biotech Co., Ltd. Antibodies targeting human claudin 18.2 and uses thereof
AU2021354827A1 (en) * 2020-09-30 2023-06-01 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pharmaceutical composition comprising antibody-drug conjugate, and use of pharmaceutical composition
CN115109154A (zh) * 2021-03-17 2022-09-27 三优生物医药(上海)有限公司 一种靶向cldn18.2的抗体或其抗原结合片段及其应用
CN115611983A (zh) * 2021-07-14 2023-01-17 三优生物医药(上海)有限公司 Cldn18.2结合分子及其用途
CN118139876A (zh) * 2021-10-19 2024-06-04 博奥信生物技术(南京)有限公司 结合cldn18.2的抗体及其用途
CN114044822B (zh) * 2021-10-28 2023-06-27 杭州博茵生物技术有限公司 血清淀粉样蛋白a抗体的重链和轻链可变区、抗体及运用
WO2023078386A1 (zh) * 2021-11-05 2023-05-11 正大天晴药业集团股份有限公司 抗cldn18.2抗体及其用途
CN114395040B (zh) * 2022-02-09 2023-12-15 东南大学附属中大医院 再生蛋白reg1a单克隆抗体及其应用
WO2023196882A1 (en) 2022-04-06 2023-10-12 Zai Lab (Us) Llc Claudin 18.2 immunohistochemistry assay and use thereof
CN117229398A (zh) * 2022-06-15 2023-12-15 中山康方生物医药有限公司 抗cldn18.2抗体、其药物组合物及用途
CN119836303A (zh) * 2022-07-08 2025-04-15 伊麦吉纳博公司 抗体及其制备和使用方法
WO2024131683A1 (zh) * 2022-12-19 2024-06-27 华润生物医药有限公司 结合cldn18.2的抗体和抗体药物偶联物及其用途
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004024617A1 (de) * 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
EP1790664A1 (en) * 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
EP1997832A1 (en) * 2007-05-29 2008-12-03 Ganymed Pharmaceuticals AG Monoclonal antibodies against Claudin-18 for treatment of cancer
WO2013167153A1 (en) * 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
WO2013174404A1 (en) * 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2014146672A1 (en) * 2013-03-18 2014-09-25 Ganymed Pharmaceuticals Ag Therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2016165762A1 (en) * 2015-04-15 2016-10-20 Ganymed Pharmaceuticals Ag Drug conjugates comprising antibodies against claudin 18.2
WO2018006882A1 (zh) * 2016-07-08 2018-01-11 科济生物医药(上海)有限公司 抗密蛋白18a2的抗体及其应用
WO2018054484A1 (en) * 2016-09-23 2018-03-29 Biontech Ag Bispecific trivalent antibodies binding to claudin 6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases

Also Published As

Publication number Publication date
SG11202105885WA (en) 2021-07-29
EP3891183A4 (en) 2022-08-31
JP2022512132A (ja) 2022-02-02
WO2020114480A1 (en) 2020-06-11
CN113423735A (zh) 2021-09-21
EP3891183A1 (en) 2021-10-13
CA3122135A1 (en) 2020-06-11
CN113423735B (zh) 2024-02-13
KR20210100655A (ko) 2021-08-17
MX2021006681A (es) 2021-11-17
AU2019391204A1 (en) 2021-06-24
JP7458399B2 (ja) 2024-03-29
BR112021011014A2 (pt) 2021-08-31
US20210380680A1 (en) 2021-12-09

Similar Documents

Publication Publication Date Title
IL268588A (en) Anti-gprc5d antibodies, compositions comprising same and uses thereof
IL285651A (en) Anti-trem2 antibodies, preparations containing them and their uses
IL291299A (en) Anti-TNFR2 antibodies, preparations containing them and their uses
IL282968A (en) Anti-NKG2A antibodies and their use
IL276950A (en) Anti-CD73 antibodies and uses thereof
IL274297A (en) Pyrazolo-piperidine-converted indole-2-carboxamides, preparations containing them and their uses
SG11202100888WA (en) Anti-avb8 antibodies and compositions and uses thereof
SG11202105885WA (en) Anti-claudin antibodies and uses thereof
IL262497A (en) Anti-il-33 antibodies, compositions, methods and uses thereof
IL275826A (en) Anti-mct1 antibodies and their uses
IL274809A (en) Antibodies against CXCR5 and their preparations and uses
IL268249A (en) Anti-tryptase antibodies, their preparations and their uses
IL289585A (en) DLL3-targeted antibodies and uses thereof
IL291027A (en) Anti-steap1 antibodies and uses thereof
SG11202009772PA (en) Anti-dll3 antibodies and uses thereof
IL280321A (en) Antibodies against CXCR2 and their uses
IL276548A (en) Binding antibodies - BCMA and their uses
SG11202009625WA (en) Anti-trem-1 antibodies and uses thereof
IL281202A (en) Anti-TNFRSF9 antibodies and uses thereof
IL277075A (en) Anti-PHF-tau antibodies and uses thereof
SG11202101037QA (en) Anti-npr1 antibodies and uses thereof
GB201901099D0 (en) Methods, uses and compositions
GB2576614B (en) Compositions, uses and methods
IL268959A (en) Antibodies with cystine mutation, preparations containing them and their uses
IL277330A (en) Anti-IL-27 antibodies and uses thereof